Azitra, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Azitra, Inc. (AZTR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $4.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $7.98M.
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.35M, a 211.85% decline year-over-year.
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $1.21M.
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$1.66M.
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$2.49M, a 190.14% decline from fiscal 2024.
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $2.76M.
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.70M.
- Azitra, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$4.55M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $4.66M 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $7.98M 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | -$2.49M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | -$3.15M 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | -$3.51M 10-Q · filed 2026-08-12 | ||||
| 2025-03-31 | -$1.35M 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | $2.76M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $5.46M 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | -$992.91K 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | $1.21M 10-Q · filed 2025-05-13 | $1.20M 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | -$1.70M 10-K · filed 2025-02-24 | ||||
| 2023-09-30 | $907.67K 10-Q · filed 2024-11-12 | ||||
| 2023-06-30 | $2.80M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | -$1.66M 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | -$4.55M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | -$2.11M 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | -$4.29M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |